market cryptocurrencies, Knowledge graph

Xinhua News Agency: China's monetary policy has changed from "prudent" to "moderately loose" to send a positive signal.Ningde's business in Europe has made progress. Through cooperation with local European giants, it has invested 30 billion RMB, with each party holding 50% of the shares. This is a new mode of exploring the sea! It is worth noting that this cooperation with Stellantis is mainly to supply lithium iron batteries and drive a new round of electrification in Europe through Ferrous lithium phosphate parity technology, which is a new opportunity from 0 to 1.Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in Europe

China Research Institute: Wang Xiuyun reduced its shareholding by 1%. At present, the company has not directly involved in the application field of humanoid robots.Easy to change the world: shareholders intend to reduce their holdings by no more than 3.05% in total;Contemporary Amperex Technology Co., Limited, as the king of volume, stopped making money everywhere and began to repay investors! Other domestic new energy giants can learn from it. Yesterday, Ning Wang opened higher and lower, and took the GEM with a bias. In the evening, the two big benefits were blessed. Can today's surge drive the GEM to rise?

Xinhua News Agency pointed out that the important meeting held on the 9th analyzed and studied the economic work in 2025, in which the expression of monetary policy attracted people's attention. After a lapse of more than 10 years, the change of monetary policy orientation to "moderately loose" once again reflects the supportive monetary policy stance and sends a positive signal, which will strongly boost the confidence of all parties and help China's economy recover.News:Among them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.